Thalidomide-O-C6-NH2 TFA is primarily utilized in biomedical research, particularly in the development of targeted therapies. Its structure allows it to act as a molecular glue, facilitating protein-protein interactions, which is crucial in the study of protein degradation pathways. This compound is often employed in the design of proteolysis-targeting chimeras (PROTACs), which are innovative therapeutic agents aimed at degrading disease-causing proteins. Additionally, it finds application in the investigation of immunomodulatory and anti-inflammatory processes, making it valuable in the study of autoimmune diseases and certain cancers. Researchers also use it to explore its potential in inhibiting angiogenesis, which is relevant in treating conditions like multiple myeloma and other malignancies.